FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310691444> ?p ?o ?g. }

• W4310691444 endingPage "S68" @default.
• W4310691444 startingPage "S67" @default.
• W4310691444 abstract "<h3>Purpose</h3> Multimodality treatment of high- and very-high risk prostate cancer has evolved tremendously in recent years to incorporate long-term androgen deprivation therapy (ADT), external-beam radiation therapy (EBRT), and brachytherapy, resulting in improved biochemical progression-free survival (bPFS). However, outcomes remain imperfect, and many patients are unwilling or unable to tolerate long-term ADT use. Existing studies show that hyperthermia is a potent and well-tolerated radiosensitizer. We report the outcomes of patients treated with short-term ADT, EBRT, and high dose-rate (HDR) brachytherapy combined with interstitial hyperthermia. <h3>Materials and Methods</h3> In a single-institution, retrospective study, we reviewed all patients with high- or very high-risk prostate adenocarcinoma who began definitive treatment between December 2016 and March 2020 with up to six months of ADT, whole-pelvis EBRT, and a combination of HDR brachytherapy boost and interstitial hyperthermia. Our primary endpoint was bPFS based on the Phoenix definition (PSA nadir +2 ng/mL) calculated from time of ADT initiation. We also report data on type of failure, survival, and toxicity. <h3>Results</h3> 56 patients were reviewed, including 21 with high-risk and 35 with very high-risk prostate adenocarcinoma. Median age was 72 years (range 52-82 years). Median duration of ADT use was 4 months (range 0-6 months). All patients received whole-pelvis EBRT of 45Gy/25fx. 55 patients (98%) received a 5.4Gy/3fx EBRT boost to the prostate and seminal vesicles. All patients received two Iridium-192 HDR implants to further boost the prostate and seminal vesicles, with each implant separated by at least one week (median 2 weeks, range 1-6 weeks) and consisting of two fractions of 5.5Gy separated by five to seven hours, for a total of 22Gy/4fx. All patients received at least one interstitial hyperthermia treatment of at least 45 minutes in between fractions of the same implant. 50 patients (89%) received both planned hyperthermia treatments of at least 60 minutes each at a goal temperature of 42-43 degrees Celsius. Median duration of follow-up was 28 months for all patients, with 34 months for high-risk and 28 months for very-high risk disease. The estimated two/three-year bPFS-rates were 100%/100% for high-risk and 92.0%/87.7% for very high-risk disease. Figure 1 represents the Kaplan-Meier curve for bPFS. Of the three very high-risk patients who failed biochemically, one failed regionally at 25 months, and two failed distantly at 15 and 23 months. There were no local failures. Two patients with very-high risk disease have died, both of unrelated lung disease at nine and 13 months. Four patients stopped their hyperthermia treatment early due to intolerance, with one developing an acute perineal burn that fully healed three months later. There were otherwise no grade 3 or higher acute toxicities. Four patients (7%) developed late grade 3 toxicities, all genitourinary-related. <h3>Conclusions</h3> Multimodality treatment of prostate cancer with short-term ADT, EBRT, HDR brachytherapy, and interstitial hyperthermia is safe and well-tolerated. For patients with high-risk disease, it provides excellent biochemical control while sparing long-term use of ADT. Patients with very high-risk disease may benefit from long-term use of ADT and/or other forms of systemic therapy. Longer follow-up and prospective trials are needed to validate our findings." @default.
• W4310691444 created "2022-12-15" @default.
• W4310691444 creator A5009943882 @default.
• W4310691444 creator A5036778852 @default.
• W4310691444 creator A5059194216 @default.
• W4310691444 creator A5078961633 @default.
• W4310691444 date "2022-11-01" @default.
• W4310691444 modified "2023-09-28" @default.
• W4310691444 title "PSOR5 Presentation Time: 11:50 AM" @default.
• W4310691444 doi "https://doi.org/10.1016/j.brachy.2022.09.099" @default.
• W4310691444 hasPublicationYear "2022" @default.
• W4310691444 type Work @default.
• W4310691444 citedByCount "0" @default.
• W4310691444 crossrefType "journal-article" @default.
• W4310691444 hasAuthorship W4310691444A5009943882 @default.
• W4310691444 hasAuthorship W4310691444A5036778852 @default.
• W4310691444 hasAuthorship W4310691444A5059194216 @default.
• W4310691444 hasAuthorship W4310691444A5078961633 @default.
• W4310691444 hasConcept C121608353 @default.
• W4310691444 hasConcept C126322002 @default.
• W4310691444 hasConcept C126894567 @default.
• W4310691444 hasConcept C141071460 @default.
• W4310691444 hasConcept C168563851 @default.
• W4310691444 hasConcept C203092338 @default.
• W4310691444 hasConcept C2775908122 @default.
• W4310691444 hasConcept C2776235491 @default.
• W4310691444 hasConcept C2777416452 @default.
• W4310691444 hasConcept C2777899217 @default.
• W4310691444 hasConcept C2779949491 @default.
• W4310691444 hasConcept C2780192828 @default.
• W4310691444 hasConcept C509974204 @default.
• W4310691444 hasConcept C71924100 @default.
• W4310691444 hasConceptScore W4310691444C121608353 @default.
• W4310691444 hasConceptScore W4310691444C126322002 @default.
• W4310691444 hasConceptScore W4310691444C126894567 @default.
• W4310691444 hasConceptScore W4310691444C141071460 @default.
• W4310691444 hasConceptScore W4310691444C168563851 @default.
• W4310691444 hasConceptScore W4310691444C203092338 @default.
• W4310691444 hasConceptScore W4310691444C2775908122 @default.
• W4310691444 hasConceptScore W4310691444C2776235491 @default.
• W4310691444 hasConceptScore W4310691444C2777416452 @default.
• W4310691444 hasConceptScore W4310691444C2777899217 @default.
• W4310691444 hasConceptScore W4310691444C2779949491 @default.
• W4310691444 hasConceptScore W4310691444C2780192828 @default.
• W4310691444 hasConceptScore W4310691444C509974204 @default.
• W4310691444 hasConceptScore W4310691444C71924100 @default.
• W4310691444 hasIssue "6" @default.
• W4310691444 hasLocation W43106914441 @default.
• W4310691444 hasOpenAccess W4310691444 @default.
• W4310691444 hasPrimaryLocation W43106914441 @default.
• W4310691444 hasRelatedWork W1977071394 @default.
• W4310691444 hasRelatedWork W2030798726 @default.
• W4310691444 hasRelatedWork W2085529113 @default.
• W4310691444 hasRelatedWork W2087149288 @default.
• W4310691444 hasRelatedWork W2138863125 @default.
• W4310691444 hasRelatedWork W2597301728 @default.
• W4310691444 hasRelatedWork W2761204422 @default.
• W4310691444 hasRelatedWork W2789553788 @default.
• W4310691444 hasRelatedWork W2946095553 @default.
• W4310691444 hasRelatedWork W3193431922 @default.
• W4310691444 hasVolume "21" @default.
• W4310691444 isParatext "false" @default.
• W4310691444 isRetracted "false" @default.
• W4310691444 workType "article" @default.